FDA inspection
Wuhan Biocause Pharmaceutical Development Co., Ltd.: FDA inspection ending Mar 14, 2025
FDA inspection 1267912 · Voluntary Action Indicated (VAI) · Wuhan
Key facts
| Inspection ID | 1267912 |
|---|---|
| Firm | Wuhan Biocause Pharmaceutical Development Co., Ltd. |
| FEI number | 3004202226 |
| Address | Bldg. 1, 4th Floor, Zhuankou Economic Development, Hi-Tech Industrial Park |
| City | Wuhan |
| Country | China |
| Fiscal year | 2025 |
| Inspection end date | Mar 14, 2025 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data